Fosaprepitant Dimeglumine Suppliers & Bulk Manufacturers
Available Forms: Injection (IV)
Available Strengths: 150 mg/vial
Reference Brands: Emend® IV (EU & US)
Category:
Oncology Cancer Care
Fosaprepitant Dimeglumine is used in oncology to prevent chemotherapy-induced nausea and vomiting. Available as a 150 mg IV injection in both the US and EU.
Fosaprepitant Dimeglumine is available in Injection (IV)
and strengths such as 150 mg/vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Fosaprepitant Dimeglumine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Fosaprepitant Dimeglumine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Fosaprepitant Dimeglumine is a trusted NK1 receptor antagonist used in oncology supportive care to prevent chemotherapy-induced nausea and vomiting (CINV). Available as a 150 mg intravenous injection, Fosaprepitant is commonly co-administered with 5-HT3 antagonists and corticosteroids. It enhances patient comfort and compliance during highly or moderately emetogenic chemotherapy. Approved in both the US and EU, and marketed under Emend® IV and as generics, it is widely used in hospital oncology departments and pharma B2B distribution. Reliable and effective, Fosaprepitant plays a critical role in managing CINV, improving quality of life for cancer patients receiving chemotherapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing